Glenmark becomes the First Company to launch Lobeglitazone for Type 2 Diabetes in India

Glenmark Pharmaceuticals Limited has become the first company to introduce Thiazolidinedione Lobeglitazone (Lobeglitazone) for the treatment of type 2 diabetes in adults in India.  An insulin sensitizer, lobeglitazone is an anti-diabetic medication that helps increase the responsiveness of human cells to insulin. The medication was initially created by the Chong Kun Dang Pharmaceutical Corporation, a company based in Seoul, Korea, and it received approval for the treatment of Type 2 Diabetes in Korea in July 2013. The company claims that the medication will be sold under the brand name LOBG and that it contains lobeglitazone (0.5 mg). To help adult diabetic patients with glycemic control, the medication is to be as prescribed by the doctor. According to studies, insulin resistance is very common in India, this makes LOBG a desirable therapeutic option for treating Type 2 diabetes in people who are insulin resistant. The manufacturing and commercialization of Lobeglitazone was previously approved by the Indian  drug authority, Drug Controller General of India, based on a randomised, double-blind Phase 3 clinical trial carried out on adult Type 2 diabetic patients, aged 18 years and older. According to the trial's findings, Lobeglitazone provides better and quicker glycemic management.